-Raising the A/S 6x out of no where, tanking the price to a near 1 year low, diluting for months. Unable to verify the T/A to verify dilution and updated O/S. Caused a lot of shareholders to dump and get out.
-Talking about a R/S at these prices doesn't make a lot of sense, didn't really make sense before the raise in A/S given the low float. The fact it's being considered makes me pretty skeptical.
-Major setback in the FDA application having to go back and do animal toxicology studies. Say what y'all want but this was not the update many had hoped for.
-Questionable "deal" with Xoles Del Pacifico. I noticed there was no mention of a Mexico distribution update on their conference call agenda.
-No word from Tony Hawk their celebrity endorser (yet).
I mean it's great they're addressing all these things in their conference call, but the fact the agenda list is SO LONG for their update should be a concern in and of itself.
There's a lot going on here that is good, don't get me wrong. I hope the ticker change and new branding help them move forward. But given what they did with the A/S back in May crushed a lot of momentum.
